A new study reveals a novel connection between aging of visceral adipose tissue and brain health. These findings are ...

CereVasc, Inc., a clinical-stage medical device company developing novel treatments for neurological diseases, announced ...

DUMAGUETE CITY, Negros Oriental (PIA) – The Philippine Health Insurance Corporation (PhilHealth) here has disbursed P469,208,060 as payment for hospital and other medical services claims in the ...

AMID a public backlash on the GCash fiasco, the Department of Finance (DOF) announced it will begin selling next month government debt papers, such as Treasury bills and bonds, through the digital ...

NXP800 Phase 1b study in patients with platinum resistant, ARID1a-mutated ovarian cancer is ongoing; Orphan Drug Designation ...

A New Drug Application has been accepted seeking accelerated approval for dordaviprone for patients with recurrent H3 ...

CereVasc today announced the first patient randomized to and treated with the eShunt system in its STRIDE clinical trial.

A new study led by Dr. Yoshinori Takei and Dr. Atsushi Sugiyama of the Department of Pharmacology, Faculty of Medicine, Toho ...

Ron Bentsur, CEO commented, “In 2024, Nuvectis made important progress in the development of our two clinical-stage drug candidates, NXP800 and ...

In addition to patrolling the body for foreign invaders, the immune system also hunts down and destroys cells that have ...

The Philippine Health Insurance Corporation in Region XI (PhilHealth-Davao) disbursed P928 million to valid member claims from December 27, 2024 to January 31, 2025. A top PhilHealth official in Davao ...